RetroBRACE - Clinical and Functional Outcomes 2 Years After Primary ACL Repair (Internal Bracing) (RetroBRACE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4031
- Department of Orthopaedics and Traumatology, University Hospital Basel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 2 years since ACL repair and Internal Brace Ligament Augmentation
Exclusion Criteria:
- Revision surgery within 2 years after primary repair (ACL, Total or Partial Knee Arthroplasty, Joint Infection, Fracture around knee level)
- BMI > 35 kg/m2
- Previous injury and surgical procedures of the contralateral knee
- Neuromuscular disorders affecting lower limb movement
- Additional pathologies that influence the mobility of the knee joints
- Inability to provide informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
joint position sense Analysis (proprioception)
Time Frame: single time point assessment (2 years after surgery)
|
Proprioception will be assessed bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA) with an active joint position sense protocol.
Participants will be positioned with hips and knees flexed at 90°.
The subjects will then actively extend their knee to the target angles of 60° or 20° flexion, respectively.
The subjects will be asked to remember this position.
Starting from 90° flexion they will then be asked to extend their knee and reproduce the remembered target flexion angle pressing a stop button when they think they reached the angle.
The difference between the perceived angle and the initial target angle will be calculated.
|
single time point assessment (2 years after surgery)
|
|
muscle strength
Time Frame: single time point assessment (2 years after surgery)
|
Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA).
|
single time point assessment (2 years after surgery)
|
|
gait analysis
Time Frame: single time point assessment (2 years after surgery)
|
Instrumented gait analysis on treadmill with embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany; 7168 sensors; area, 1.5 * 0.5 m; range, 1-120 N/cm2; precision, 1-120 N/cm2 ± 5%; sampling rate, 120 Hz) and on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz).
Patients walk barefoot for 2 minutes at 0% slope at their preferred walking speed and at 1 m/s followed by walking at preferred walking speed.
The treadmill speed will be increased to preferred running speed, and data for 2 minutes running will be recorded.
Maximum flexion and extension angles and joint moments will be computed using the Biomove software (Stanford University).
|
single time point assessment (2 years after surgery)
|
|
maximum jump height (cm)
Time Frame: single time point assessment (2 years after surgery)
|
Participants will perform three single leg hops on each leg.
Maximum jump height will be determined as the highest position of the pelvis marker compared to a standing trial
|
single time point assessment (2 years after surgery)
|
|
Euroquol 5 Dimensions (EQ-5D-5L)
Time Frame: single time point assessment (2 years after surgery)
|
EQ-5D-5L questionnaire measuring generic health Status; descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.
This decision results in a 1-digit number that expresses the level selected for that dimension.
The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 55555 (having extreme problems in all dimensions).
|
single time point assessment (2 years after surgery)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Annegret Muendermann, Prof. Dr. MD, Department of Orthopaedics and Traumatology Universitätsspital Basel
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019-00491; ch19Jakob
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rupture
-
NCT01440348CompletedRupture of Anterior Cruciate Ligament | Rupture of Posterior Cruciate Ligament
-
NCT06990100Completed
-
NCT05585528Terminated
-
NCT05420974Not yet recruitingMeniscus Rupture
-
NCT06602414Completed
-
NCT06420648RecruitingFlexor Tendon Rupture
-
NCT04579809Not yet recruitingFlexor Tendon Rupture
-
NCT04503421Completed
-
NCT04263493CompletedAchilles Tendon Rupture
Clinical Trials on functional outcome measurement
-
NCT00731796SuspendedHemianopsia, Homonymous
-
NCT04721080UnknownQuality of Life | Tuberculosis | Copd
-
NCT05424614RecruitingCerebral Hemorrhage | Artificial Intelligence | Prognosis
-
NCT04153448Completed
-
NCT04182269Completed
-
NCT05882981CompletedMuscle Strength | Functional Capacity | Functional Performance | Flexibility | High Femoral Anteversion
-
NCT02073695Terminated
-
NCT06976593Not yet recruitingQuality of Life | Exercise | Hormonal Therapy | Functional Capacity | Muscle Oxygenation | Breast Cancer Survivorship | Near-infrared Spectroscopy
-
NCT04161313CompletedCystic Fibrosis | Primary Ciliary Dyskinesia
-
NCT04429165CompletedInjury of the Anterior Cruciate Ligament (ACL)